NERV Minerva Neurosciences Inc
Price (delayed)
$1.74
Market cap
$12.17M
P/E Ratio
9.16
Dividend/share
N/A
EPS
$0.19
Enterprise value
-$9.29M
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
Highlights
The company's net income has surged by 143% QoQ and by 105% YoY
The EPS has surged by 142% since the previous quarter and by 104% year-on-year
The company's quick ratio fell by 38% YoY but it rose by 27% QoQ
Minerva Neurosciences's equity has decreased by 19% QoQ but it has increased by 10% YoY
Key stats
What are the main financial stats of NERV
Market
Valuations
Earnings
Shares outstanding
6.99M
Market cap
$12.17M
Enterprise value
-$9.29M
Price to earnings (P/E)
9.16
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
-6.46
EV/EBITDA
-6.36
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$21.85M
Net income
$1.44M
EBIT
$1.44M
EBITDA
$1.46M
Free cash flow
-$19.55M
Per share
Balance sheet
Liquidity
EPS
$0.19
EPS diluted
$0.19
Free cash flow per share
-$2.58
Book value per share
-$3.67
Revenue per share
$0
TBVPS
$2.94
Total assets
$37.14M
Total liabilities
$62.84M
Debt
$0
Equity
-$25.69M
Working capital
$19.43M
Debt to equity
0
Current ratio
7.85
Quick ratio
7.57
Net debt/EBITDA
-14.69
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
3.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
4.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NERV stock price
How has the Minerva Neurosciences stock price performed over time
Intraday
3.57%
1 week
4.82%
1 month
-15.12%
1 year
-38.3%
YTD
-21.68%
QTD
-21.68%
Financial performance
How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.85M
Net income
$1.44M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 143% QoQ and by 105% YoY
NERV's operating income is up by 11% since the previous quarter and by 5% year-on-year
Growth
What is Minerva Neurosciences's growth rate over time
Valuation
What is Minerva Neurosciences stock price valuation
P/E
9.16
P/B
N/A
P/S
N/A
EV/EBIT
-6.46
EV/EBITDA
-6.36
EV/Sales
N/A
The EPS has surged by 142% since the previous quarter and by 104% year-on-year
Minerva Neurosciences's equity has decreased by 19% QoQ but it has increased by 10% YoY
Efficiency
How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has surged by 149% QoQ and by 107% YoY
Dividends
What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NERV.
Financial health
How did Minerva Neurosciences financials performed over time
The total assets is 41% less than the total liabilities
The company's quick ratio fell by 38% YoY but it rose by 27% QoQ
Minerva Neurosciences's current ratio has decreased by 38% YoY but it has increased by 26% QoQ
The debt is 100% more than the equity
Minerva Neurosciences's equity has decreased by 19% QoQ but it has increased by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.